Literature DB >> 31174441

Association between EPHX1 polymorphism rs1051740 and the risk of ovarian cancer: a meta-analysis.

Ying Jin1.   

Abstract

Objective: We carried out a meta-analysis of case-control studies to determine whether epoxide hydrolase 1 (EPHX1) gene polymorphism rs1051740 was related to the risk of ovarian cancer.
Methods: Electronic databases were searched for relevant articles published in English or Chinese language. We calculated crude odds ratios (ORs) with their 95% confidence intervals (95% CIs) to assess the relationship of EPHX1 polymorphism rs1051740 with ovarian cancer risk. In addition, subgroup analyses were also conducted based on ethnicity and control source. Between-study heterogeneity was inspected with Q test and I2 statistic.
Results: Five eligible studies with a total of 1919 ovarian cancer patients and 1829 controls were ultimately included in the present meta-analysis. Overall results demonstrated that the association between EPHX1 polymorphism rs1051740 and ovarian cancer risk had no statistical significance either in total analysis or in subgroup analyses by ethnicity and source of control.
Conclusion: EPHX1 polymorphism rs1051740 may have no independent effect on ovarian cancer susceptibility.

Entities:  

Keywords:  EPHX1; meta-analysis; ovarian cancer; polymorphism

Mesh:

Substances:

Year:  2019        PMID: 31174441     DOI: 10.1080/21691401.2019.1622551

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  2 in total

1.  The effect of folate intake on ovarian cancer risk: A meta-analysis of observational studies.

Authors:  Kena Wang; Qinwei Zhang; Jianhua Yang
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

Review 2.  Association between XRCC3 rs861539 Polymorphism and the Risk of Ovarian Cancer: Meta-Analysis and Trial Sequential Analysis.

Authors:  Siya Hu; Yunnan Jing; Fangyuan Liu; Fengjuan Han
Journal:  Biomed Res Int       Date:  2022-08-08       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.